Welcome, and let us introduce ourselves!
Our goal at Woven Data is to provide analytical tools and managed services to drive commercial success for pharmaceutical manufacturers. In this blog, we'll be covering our experiences in all of the areas that we touch: market access, government pricing, contracting, and M&A diligence and reporting. You will be seeing my name on many of these posts, so I figure this is as good a time as any to introduce myself.
Prior to co-founding Woven Data, I was the VP of Market Access and Commercial Operations at Covis Pharma, a global pharma company. I was lucky enough to be a part of the executive team that successfully built a product portfolio (twice) and then divested those products. As we built our product portfolio, my responsibilities included contracting decisions - both government and commercial, as well as all the strategic initiatives for our branded portfolio: patient programs, copay cards, marketing, etc. Due to the diverse nature of our product mix there was no "universal playbook", and we embarked on numerous market access pilot programs.
The market access vantage point gave me a rare opportunity to support and shape the product diligence and acquisition strategy as part of our internal business development team, and then onboard those products into our portfolio, and eventually divest them. Those years at Covis were tremendous practice for assessing the market, finding products that fit, and onboarding them.
I want to share my thoughts on the approaches, systems and reports I have found to work, and that I believe are foundational building blocks independent of your specific product portfolio and market access strategy. Of course, these happen to be the things we are building at Woven Data. Since there is indeed no universal playbook for market access in pharma, I love to hear back about what challenges or questions may be top of your mind, and anything you would like me to cover.
You can get in touch with me via LinkedIn or one of our contact forms. Welcome!
Published on Feb. 1, 2021 by Scott Hoffman